Sun Pharma’s Ilumya expansion bid gets USFDA nod for review

Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ZMkVv2
via IFTTT